Home Preclinical development

Preclinical development

REGN3124-PBD a Novel EGFRvIII-selective ADC Shows Promise Against Glioblastoma Multiforme Patient-derived Xenografts

Glioblastoma Multiforme (GBM) is a highly aggressive primary malignant brain tumor with few specific molecular targets and poor therapeutic...

Preclinical Study Supports Continued Evaluation of CD25-targeted ADC in Selected Advanced Solid Tumors

Preclinical data for camidanlumab tesirine (formerly ADCT-301; ADC Therapeutics), published in the Journal for ImmunoTherapy of Cancer, the online...